Craxì Antonio
Gastroenterology and Liver Unit, Di.Bi.M.I.S., University of Palermo, Palermo, Italy.
Antivir Ther. 2009;14(8):1045-9. doi: 10.3851/IMP1428.
The recommended treatment duration with pegylated interferon-alpha plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these patients can be effectively treated for a 24-week period without any significant decreases in sustained virological response rates. The aim of this review was to consider the existing clinical evidence regarding the use of a 24-week treatment schedule among genotype 1 patients and to highlight the characteristics of patients most suitable for this shortened treatment schedule.
聚乙二醇化干扰素-α联合利巴韦林治疗丙型肝炎病毒（HCV）基因1型感染患者的推荐疗程为48周。有趣的是，基因1型患者中的一个亚群在治疗开始后HCV RNA水平迅速下降，并获得快速病毒学应答，快速病毒学应答定义为治疗第4周时HCV RNA检测不到。多项研究表明，这些患者可以接受24周的有效治疗，且持续病毒学应答率不会有任何显著下降。本综述的目的是考量关于基因1型患者使用24周治疗方案的现有临床证据，并突出最适合这种缩短治疗方案的患者特征。
